Skip to main content
Clinical Trials/JPRN-jRCTs041200072
JPRN-jRCTs041200072
Active, not recruiting
Phase 2

COVID-19 Prevention of worsening of symptoms in asymptomatic to mild patients by combined use of kakkonto and hochuekkito:Exploratory open-label randomized controlled trial - HKCOV

Ogawa Keiko0 sites100 target enrollmentDecember 10, 2020
ConditionsCOVID-19

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
COVID-19
Sponsor
Ogawa Keiko
Enrollment
100
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 10, 2020
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Ogawa Keiko

Eligibility Criteria

Inclusion Criteria

  • 1\) SARS\-CoV\-2 is positive in nucleic acid detection or antigen test.
  • 2\) 20years old or over
  • 3\) Asymptomatic or mild symptoms.

Exclusion Criteria

  • 1\) Administration of kampo medicine (Juzendaihoto,Ninjinyoueito, Hochuekkito, Seishoekkito, Rikkunshito, Shikunshito, Kihito, Kamikihito) within the last two weeks
  • 2\) Persons with a history of hypersensitivity to Hochuekkito or Kakkonto
  • 3\) Those who participated in other clinical intervention studies (studies) within 3 months before the start of study drug administration
  • 4\) A person who is judged by the principal investigator or the investigator to be inappropriate as a research subject.
  • 5\) Those who are pregnant, may be pregnant, or are breastfeeding

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
High dose Vitamin D in Preventing Aggravation of COVID-19SARS-COV-2 positive patientsMedDRA version: 23.0Level: LLTClassification code 10084382Term: Coronavirus disease 2019System Organ Class: 100000004862MedDRA version: 20.0Level: PTClassification code 10050713Term: Vitamin DSystem Organ Class: 10022891 - InvestigationsMedDRA version: 20.0Level: LLTClassification code 10013097Term: Disease aggravationSystem Organ Class: 100000004867Therapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2020-001793-30-DKCopenhagen University Hospital of Bispebjerg480
Completed
Not Applicable
International ALLIANCE Study of Therapies to prevent progression of COVID-19, a randomized trialCOVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseases
ACTRN12620000557932AProf Dr Karin Ried446
Recruiting
Phase 1
Therapies to prevent progression of COVID-19 in outpatients: The 'Primary Care Australian COVID-19 Therapeutics' (PACT) Trial
ACTRN12622000386730AProf Dr Karin Ried300
Withdrawn
Not Applicable
International ALLIANCE Study of Therapies to prevent progression of COVID-19, a randomized trial - Stage 2COVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseases
ACTRN12622000309785AProf Dr Karin Ried200
Not yet recruiting
Phase 3
Prevention and treatment for covid-19 associated severe pneumonia in The Gambia: a randomized clinical trial (PaTS-COVID) COVID-19
PACTR202101544570971Medical Research Council Unit The Gambia at LSHTM1,200